Brief: United Laboratories International Says NMPA Approves Clinical Trial Application For Dupilumab Bio-Similar For Atopic Dermatitis
22/04/2026 16:25
April 22 (Reuters) - United Laboratories International Holdings Ltd 3933.HK: CHINA NMPA APPROVES CLINICAL TRIAL APPLICATION FOR DUPILUMAB BIO-SIMILAR FOR ATOPIC DERMATITIS Further company coverage: 3933.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on United Laboratories International Holdings
See all newsBrief: United Laboratories International Receives Milestone Payment From Novo
Brief: United Laboratories International Says NMPA Accepts Insulin Degludec And Liraglutide Injection Marketing Registration Application
Brief: United Laboratories International Posts HY Profit Attributable RMB 347.6 Million
China's United Laboratories half-year profit drops 82%
Brief: United Laboratories International Expects HY Net Profit RMB 340 Million